Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the Emeryville, ...

XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago. These ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

XOMA Royalty recorded total income and revenues of $11.1 million for the second quarter of 2024, which included $4.9 million in estimated income associated with two commercial products in our ...

XOMA Royalty Corporation has announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Cumulative Preferred Stock, payable on or about January 15 ...